A change in leadership could offer the New England Journal of Medicine the chance to re-make itself, write Retraction Watch's Adam Marcus and Ivan Oransky, at Stat News.
ProPublica writes that the New England Journal of Medicine may not be keeping up with the times.
By Turna Ray
Cepheid's Xpert MTB/RIF test received a vote of confidence for its ability to diagnose TB and rifampicin resistance in remote and resource-poor regions of the world, according to the results of a New England Journal of Medicine study.
Findings in a NEJM study this week challenged previously reported data that alleles in the CYP2C19 gene can limit how certain carriers of the polymorphisms respond to Plavix.
A man has confessed to the rape and murder of developmental biologist Suzanne Eaton, according to the New York Times.
The Irish Times reports that US lawmakers and law enforcement agencies are concerned about ties between the US and Chinese genomics firms.
Parents of children with spinal muscular atrophy tell the Washington Post they are pushing to get insurance coverage of Novartis's Zolgensma.
In PNAS this week: gene mutations in individuals with syndromic craniosynostosis, putative colorectal cancer drivers, and more.